Afaf El Katerji

Dr. Afaf El Katerji

Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Beyrouth, Lebanon
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in Polymers
Verified
Journal Article
Open access
PDF file
GSGhassan Mohamad Sonji
Ghassan Mohamad Sonji
NSNada Mohamad Sonji
Nada Mohamad Sonji
AKAfaf El Katerji
Afaf El Katerji
MRMohamad Rahal
Mohamad Rahal
Atmospheric water harvesting (AWH) offers a decentralized and renewable solution to global freshwater scarcity. Bio-derived and hybrid aerogels, characterized by ultra-high porosity and hierarchical pore structures, show significant potential for high water uptake and energy-efficient, low-temperature regeneration. This PRISMA-guided systematic review synthesizes evidence on silica, carbon, MOF-integrated, and bio-polymer aerogels, emphasizing green synthesis and circular design. Our analysis shows that reported water uptake reaches up to 0.32 g·g−1 at 25% relative humidity (RH) and 3.5 g·g−1 at 90% RH under static laboratory conditions. Testing protocols vary significantly across studies, and dynamic testing typically reduces these values by 20–30%. Ambient-pressure drying and solar-photothermal integration enhance sustainability, but performance remains highly dependent on device architecture and thermal management. Techno-economic models estimate water costs from USD 0.05 to 0.40 per liter based on heterogeneous assumptions and system boundaries. However, long-term durability and real-world environmental stressor data are severely underreported. Bridging these gaps is essential to move from lab-scale promise to scalable, commercially viable deployment. We propose a strategic roadmap toward 2035, highlighting the need for improved material stability, standardized testing protocols, and comprehensive life cycle assessments to ensure the global viability of green aerogel technologies.

6 August 2026 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
GSGhassan Mohamad Sonji
Ghassan Mohamad Sonji
NSNada Mohamad Sonji
Nada Mohamad Sonji
AKAfaf El Katerji
Afaf El Katerji
Introduction: Sleep fragmentation is associated with preclinical Alzheimer's disease (AD) and may precede cognitive symptoms by years. Sleep disruption is a factor amenable to objective assessment. Evidence suggests that fragmented sleep impairs the brain's glymphatic clearance system, promoting amyloid-beta and tau accumulation. This raises the possibility that dual orexin receptor antagonists (DORAs) may influence sleep-related processes in preclinical AD, though direct human evidence is lacking. Methods: This study conducted a PRISMA-ScR scoping review from 2012 to June 2025 evaluating plasma p-tau217, Aβ42/40 ratios, DTI-ALPS, sleep architecture, and APOE ε4 genotype. This study assessed evidence quality using an exploratory confidence-rating approach. Results: In some transgenic AD models, orexin antagonism reduced amyloid plaque burden. Human data remain limited. In a randomized placebo-controlled four-week trial involving 285 participants with probable AD dementia and insomnia, suvorexant significantly increased total sleep time relative to placebo. However, biomarker changes, glymphatic function, and long-term cognitive outcomes were not evaluated. Thus, current evidence for disease-modifying effects in humans is very limited and uncertain. Discussion: Whether DORAs influence glymphatic clearance in humans remains unknown. One untested mechanistic question concerns the role of noradrenergic vascular pulsations during sleep. Future trials should incorporate integrated endpoints including fluid biomarkers, neuroimaging, and sleep physiology. Conclusion: Preclinical findings remain preliminary and lack human validation. This review maps existing biomarker literature to generate mechanistic hypotheses; no integrative risk model, threshold combination, or stratification tool is proposed. Mechanistic proof-of-concept studies must precede any consideration of larger trials or translational application.




7 July 2026 in Therapeutic Delivery
Verified
Journal Article
Closed access
GSGhassan Mohamad Sonji
Ghassan Mohamad Sonji
NSNada Mohamad Sonji
Nada Mohamad Sonji
AKAfaf El Katerji
Afaf El Katerji
Naturally derived excipients such as lecithin, chitosan, and hyaluronic acid offer biocompatibility for injectable nanomedicines, although material variability may limit clinical translation. This systematic review evaluated pharmacokinetic performance alongside regulatory and quality gaps. PubMed, Scopus, Web of Science, and Embase (2002-2025) were searched for nanocarriers (≤500 nm) incorporating naturally derived excipients with pharmacokinetic or physicochemical data. Risk of bias was assessed using SYRCLE, Cochrane RoB 2.0, ROBINS-I, and an adapted Newcastle-Ottawa Scale. Descriptive synthesis was performed due to heterogeneity. The protocol was registered on OSF (10.17605/OSF.IO/6XA5M). Sixty-three studies met inclusion criteria (48 preclinical, 15 clinical). Among preclinical studies reporting pharmacokinetic parameters, median 2.4-fold plasma exposure (n = 15) and 2.9-fold tumor accumulation (n = 18) increases were observed versus free drug. No included studies reported ICH Q8-aligned quality by design (QbD), multivariate modeling, or artificial intelligence. Fewer than 10% reported detailed compositional characterization or impurity profiling relevant to parenteral development. Naturally derived excipients were associated with pharmacokinetic enhancement, but inconsistent characterization and limited adoption of structured QbD approaches may hinder regulatory translation. Certainty of evidence across outcomes was low, and prospective validation of proposed QbD strategies remains necessary.